Clinical Trial Update: F-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Cancer Undergoing Endocrine-Targeted Therapy [NA]

View source ↗

Summary

Clinical trial assessing F-18 FES PET/CT to measure hormone expression in estrogen receptor–positive breast cancer during endocrine-targeted therapy; study is t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer

Snippet

Sponsor: University of Washington | Conditions: Estrogen Receptor Positive, Recurrent Breast Carcinoma | NA | Status: TERMINATED | Results posted: 2020-02-11